Fig. 9. Effect of cardamonin on the immunohistochemical testicular expression of an apoptotic marker (caspase-3) in different experimental groups.
Immunohistochemical stain, 200×, bar = 50 μm. (A) Testis of the control group showing mild expression of caspase-3 antibody (arrows). (B) Testis of the CARD group showing little expression of caspase-3 antibody (arrows). (C) Testis of the untreated DM group showing marked expression of caspase-3 antibody in the spermatogenic cells of seminiferous tubules (arrows). (D) Testis of the DM + GLIB group showing a mild decrease in the expression of caspase-3 antibody in spermatogenic cells (arrows). (E) Testis of the DM + CARD group showing a moderate decrease in the expression of caspase-3 antibody in spermatogenic cells (arrows). (F) Testis of the DM + GLIB + CARD group showing a marked decrease in the expression of caspase-3 antibody in spermatogenic cells (arrows). (G) Results showing a significant increase in the caspase-3 labelling index in the untreated diabetic testicular tissue in comparison with the control. Treatment of diabetic rats with CARD produced a marked decrease in the labelling index of the caspase-3-stained area as compared with the untreated diabetic group. The maximum decrease in the immunoreactive stain was found in the DM + GLIB + CARD group when compared with the other treated diabetic groups. CARD, normal rats treated with cardamonin; DM, untreated diabetic group; DM + GLIB, diabetic rats treated with glibenclamide; DM + CARD, diabetic rats treated with cardamonin; DM + GLIB + CARD, diabetic rats treated with both glibenclamide and cardamonin. *Represents significance compared with the control group; #represents significance compared with the DM group; $represents significance compared with the DM + GLIB group; @repre-sents significance compared with the DM + CARD group.
© Korean J Physiol Pharmacol
